Nasdaq · CIK 0001430306
TNXP Tonix Pharmaceuticals Holding Corp.
Insider trading from SEC Form 4. Last filing 43 d ago. Close $7.30 on Oct 9, 2026, +0% from the 52-week low and -68% from the high.
In brief
Tonix Pharmaceuticals Holding Corp. (TNXP) has 36 SEC Form 4 filings on file from 13 insiders, the latest filed on Aug 31, 2026. In the last 90 days insiders made 2 open-market buys worth $40k and 0 open-market sells worth $0, net +$40k.
10 open-market trades have been scored at TNXP. The newest: Seth Lederman (Chief Executive Officer) bought $28k of stock on Aug 27, 2026, filed Aug 31, 2026, scored 57 (moderate). The largest of the 10 shown: Seth Lederman (Chief Executive Officer) bought $223k on Mar 18, 2026, scored 65 (notable). 2 insiders bought within 14 days of each other around Aug 27, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Tonix Pharmaceuticals Holding Corp., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Seth Lederman Chief Executive Officer buy | $28k 2,000 shares | +22% | +43% from low-58% from high | |
| 39Weak | Richard H Bagger director buy | $13k 1,000 shares | - | +30% from low-67% from high | |
| 58Moderate | Carolyn E. Taylor director buy | $15k 1,415 shares | +339% | +7% from low-82% from high | |
| 80Strong | Seth Lederman Chief Executive Officer buy | $59k 5,000 shares | +125% | +4% from low-81% from high | |
| 63Notable | Richard Newcomb Stillwell director buy | $58k 5,000 shares | - | +6% from low-81% from high | |
| 52Moderate | Seth Lederman Chief Executive Officer buy | $63k 5,000 shares | +33% | +14% from low-78% from high | |
| 65Notable | Seth Lederman Chief Executive Officer buy | $223k 15,000 shares | first purchase | +7% from low-77% from high | |
| 31Weak | Carolyn E. Taylor director buy | $15k 418 shares | - | - | |
| 31Weak | James Treco director buy | $9,000 250 shares | - | - | |
| 44Moderate | Seth Lederman Chief Executive Officer buy | $86k 4,000 shares | first purchase | - |
Transactions
Every row filed, 46 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Seth Lederman Chief Executive Officer | POpen-market purchase Common Stock, $0.001 par valueindirect: By IRA Account | +2,000 | $13.79 | $28k | 11,005 | 43 d ago |
| Aug 20, 2026 | Richard H Bagger director | POpen-market purchase Common Stock, par value $0.001 | +1,000 | $12.60 | $13k | 1,000 | Aug 24, 2026 |
| Jun 30, 2026 | Bradley Saenger Chief Financial Officer | JOther Common Stock, $0.001 par value | +1,453 | $10.91 | $16k | 2,154 | Jul 9, 2026 |
| Jun 12, 2026 | Carolyn E. Taylor director | POpen-market purchase Common Stock, $0.001 par value | +1,415 | $10.55 | $15k | 1,833 | Jun 15, 2026 |
| Jun 9, 2026 | Seth Lederman Chief Executive Officer | POpen-market purchase Common Stock, $0.001 par value | +5,000 | $11.79 | $59k | 9,005 | Jun 9, 2026 |
| Jun 8, 2026 | Richard Newcomb Stillwell director | POpen-market purchase Common Stock, $0.001 par value | +5,000 | $11.65 | $58k | 5,000 | Jun 9, 2026 |
| May 12, 2026 | Richard Newcomb Stillwell director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| May 12, 2026 | James Treco director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| May 12, 2026 | Carolyn E. Taylor director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| May 12, 2026 | Adeoye Y Olukotun director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| May 12, 2026 | James Randolph Hunter Jr director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| May 12, 2026 | David L Grange director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| May 12, 2026 | Margaret Smith Bell director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| May 12, 2026 | Richard H Bagger director | AGrant or award Stock Optionderivative | +22,700 | $0.00 | $0 | 22,700 | May 14, 2026 |
| Mar 31, 2026 | Seth Lederman Chief Executive Officer | POpen-market purchase Common Stock, $0.001 par valueindirect: By IRA Account | +5,000 | $12.62 | $63k | 20,001 | Apr 1, 2026 |
| Mar 18, 2026 | Seth Lederman Chief Executive Officer | POpen-market purchase Common Stock, $0.001 par valueindirect: By IRA Account | +15,000 | $14.89 | $223k | 15,001 | Mar 18, 2026 |
| Feb 24, 2026 | Siobhan Fogarty Chief Technology Officer | AGrant or award Stock Optionderivative | +39,012 | $0.00 | $0 | 39,012 | Feb 26, 2026 |
| Feb 24, 2026 | Seth Lederman Chief Executive Officer | AGrant or award Stock Optionderivative | +134,504 | $0.00 | $0 | 134,504 | Feb 26, 2026 |
| Feb 24, 2026 | Gregory M Sullivan Chief Medical Officer | AGrant or award Stock Optionderivative | +39,012 | $0.00 | $0 | 39,012 | Feb 26, 2026 |
| Feb 24, 2026 | Jessica Edgar Morris Chief Operating Officer | AGrant or award Stock Optionderivative | +39,012 | $0.00 | $0 | 39,012 | Feb 26, 2026 |
| Feb 24, 2026 | Bradley Saenger Chief Financial Officer | AGrant or award Stock Optionderivative | +39,012 | $0.00 | $0 | 39,012 | Feb 26, 2026 |
| Feb 24, 2026 | Bradley Saenger Chief Financial Officer | AGrant or award Stock Optionderivative | +39,011 | $0.00 | $0 | 39,011 | Feb 26, 2026 |
| Feb 24, 2026 | Gregory M Sullivan Chief Medical Officer | AGrant or award Stock Optionderivative | +39,011 | $0.00 | $0 | 39,011 | Feb 26, 2026 |
| Feb 24, 2026 | Seth Lederman Chief Executive Officer | AGrant or award Stock Optionderivative | +134,503 | $0.00 | $0 | 134,503 | Feb 26, 2026 |
| Feb 24, 2026 | Siobhan Fogarty Chief Technology Officer | AGrant or award Stock Optionderivative | +39,011 | $0.00 | $0 | 39,011 | Feb 26, 2026 |
| Feb 24, 2026 | Jessica Edgar Morris Chief Operating Officer | AGrant or award Stock Optionderivative | +39,011 | $0.00 | $0 | 39,011 | Feb 26, 2026 |
| Aug 21, 2025 | Carolyn E. Taylor director | POpen-market purchase Common Stock, par value $0.001 | +418 | $36.03 | $15k | 418 | Aug 21, 2025 |
| Aug 20, 2025 | James Treco director | POpen-market purchase Common Stock, par value $0.001 | +250 | $36.00 | $9,000 | 250 | Aug 20, 2025 |
| Jun 12, 2025 | James Randolph Hunter Jr director | AGrant or award Stock Optionderivative | +7,740 | $0.00 | $0 | 7,740 | Jun 13, 2025 |
| May 13, 2025 | Richard Newcomb Stillwell director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | May 15, 2025 |
| May 13, 2025 | James Treco director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | May 15, 2025 |
| May 13, 2025 | Carolyn E. Taylor director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | May 15, 2025 |
| May 13, 2025 | Adeoye Y Olukotun director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | May 15, 2025 |
| May 13, 2025 | David L Grange director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | May 15, 2025 |
| May 13, 2025 | Margaret Smith Bell director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | May 15, 2025 |
| May 13, 2025 | Richard H Bagger director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | May 15, 2025 |
| May 15, 2025 | Seth Lederman Chief Executive Officer | POpen-market purchase Common Stock, $0.001 par value | +4,000 | $21.55 | $86k | 4,005 | May 15, 2025 |
| Feb 5, 2025 | Richard H Bagger director | JOther Common Stock, par value $0.001 | -0 | $0.20 | $0 | 0 | Feb 28, 2025 |
| Feb 5, 2025 | Margaret Smith Bell director | JOther Common Stock, par value $0.001 | -1 | $0.15 | $0 | 0 | Feb 28, 2025 |
| Feb 25, 2025 | Siobhan Fogarty Chief Technology Officer | AGrant or award Stock Optionderivative | +13,500 | $0.00 | $0 | 13,500 | Feb 27, 2025 |
| Feb 25, 2025 | Siobhan Fogarty Chief Technology Officer | AGrant or award Stock Optionderivative | +13,500 | $0.00 | $0 | 13,500 | Feb 27, 2025 |
| Feb 5, 2025 | Seth Lederman Chief Executive Officer | JOther Common Stock, $0.001 par value | -5 | $3.38 | $18 | 5 | Feb 27, 2025 |
| Feb 5, 2025 | Seth Lederman Chief Executive Officer | JOther Common Stock, $0.001 par valueindirect: By IRA Account | -0 | $3.30 | $1 | 1 | Feb 27, 2025 |
| Feb 5, 2025 | Seth Lederman Chief Executive Officer | JOther Common Stock, $0.001 par valueindirect: By Spouse | -1 | $0.15 | $0 | 0 | Feb 27, 2025 |
| Feb 25, 2025 | Seth Lederman Chief Executive Officer | AGrant or award Stock Optionderivative | +123,958 | $0.00 | $0 | 123,958 | Feb 27, 2025 |
| Feb 25, 2025 | Seth Lederman Chief Executive Officer | AGrant or award Stock Optionderivative | +123,958 | $0.00 | $0 | 123,958 | Feb 27, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Richard H Baggerdirector
- Margaret Smith Belldirector
- Siobhan FogartyChief Technology Officer
- David L Grangedirector
- James Randolph Hunter Jrdirector
- Seth LedermanChief Executive Officer
- Jessica Edgar MorrisChief Operating Officer
- Adeoye Y Olukotundirector
- Bradley SaengerChief Financial Officer
- Gregory M SullivanChief Medical Officer
- Richard Newcomb Stillwelldirector
- Carolyn E. Taylordirector
- James Trecodirector
Questions about TNXP
Answered from the filings on this page, as of the latest one.
Are insiders buying TNXP?
As of Aug 31, 2026, SEC Form 4 filings show 2 open-market buys worth $40k by 2 insiders and 0 open-market sells worth $0 by 0 insiders at Tonix Pharmaceuticals Holding Corp. in the last 90 days, net +$40k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade TNXP on the open market?
Seth Lederman (Chief Executive Officer) bought $28k of TNXP on Aug 27, 2026 and filed the Form 4 on Aug 31, 2026. InsiderTell scored 57 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Tonix Pharmaceuticals Holding Corp.?
13 people have filed a Form 4 at Tonix Pharmaceuticals Holding Corp., among them Richard H Bagger (director), Margaret Smith Bell (director), Siobhan Fogarty (Chief Technology Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.